| Dr Kamran Mohammed Riaz, MD | |
|
608 Stanton L Young Blvd, Oklahoma City, OK 73104-5065 | |
| (405) 271-6060 | |
| (405) 271-3013 |
| Full Name | Dr Kamran Mohammed Riaz |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 16 Years |
| Location | 608 Stanton L Young Blvd, Oklahoma City, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326276965 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| O U Medical Center | Oklahoma city, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dean Mcgee Eye Institute | 3779495353 | 40 |
News Archive
In an observational study, Mayo Clinic researchers report that the combination of casirivimab and imdevimab - two monoclonal antibody treatments under Food and Drug Administration emergency use authorization - keep high-risk patients out of the hospital when infected with mild to moderate COVID-19. The findings appear in The Lancet's EClinicalMedicine.
PURE Bioscience, Inc., creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that Health Canada has approved PURE™ Hard Surface disinfectant for use in food premises, hospitals and health care facilities, domestic locations and institutional and industrial premises.
University of North Carolina Lineberger Comprehensive Cancer Center researchers have found that by helping to form clots within tumors, immune cells that flock to a particular type of lung cancer are actually building a foundation for the tumor to spread within the body.
In a joint post in the Center for Global Development's (CGD) "Global Health Policy" blog, Amanda Glassman, director of global health policy and a senior fellow at the CGD; research assistant Denizhan Duran; and Kate McQueston, program coordinator to the global health policy team, recap major global health events in 2012, linking to previous coverage of highlighted issues.
Treatment with denosumab, a drug targeted against a protein that helps promote bone destruction, decreased the number of tumor giant cells in patients with giant-cell tumor of the bone, and increased new bone formation, according to the results of a phase II study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
› Verified 1 days ago
| Entity Name | Dean Mcgee Eye Institute |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245209675 PECOS PAC ID: 3779495353 Enrollment ID: O20031103000297 |
News Archive
In an observational study, Mayo Clinic researchers report that the combination of casirivimab and imdevimab - two monoclonal antibody treatments under Food and Drug Administration emergency use authorization - keep high-risk patients out of the hospital when infected with mild to moderate COVID-19. The findings appear in The Lancet's EClinicalMedicine.
PURE Bioscience, Inc., creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that Health Canada has approved PURE™ Hard Surface disinfectant for use in food premises, hospitals and health care facilities, domestic locations and institutional and industrial premises.
University of North Carolina Lineberger Comprehensive Cancer Center researchers have found that by helping to form clots within tumors, immune cells that flock to a particular type of lung cancer are actually building a foundation for the tumor to spread within the body.
In a joint post in the Center for Global Development's (CGD) "Global Health Policy" blog, Amanda Glassman, director of global health policy and a senior fellow at the CGD; research assistant Denizhan Duran; and Kate McQueston, program coordinator to the global health policy team, recap major global health events in 2012, linking to previous coverage of highlighted issues.
Treatment with denosumab, a drug targeted against a protein that helps promote bone destruction, decreased the number of tumor giant cells in patients with giant-cell tumor of the bone, and increased new bone formation, according to the results of a phase II study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kamran Mohammed Riaz, MD 608 Stanton L Young Blvd, Oklahoma City, OK 73104-5065 Ph: (405) 271-6060 | Dr Kamran Mohammed Riaz, MD 608 Stanton L Young Blvd, Oklahoma City, OK 73104-5065 Ph: (405) 271-6060 |
News Archive
In an observational study, Mayo Clinic researchers report that the combination of casirivimab and imdevimab - two monoclonal antibody treatments under Food and Drug Administration emergency use authorization - keep high-risk patients out of the hospital when infected with mild to moderate COVID-19. The findings appear in The Lancet's EClinicalMedicine.
PURE Bioscience, Inc., creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that Health Canada has approved PURE™ Hard Surface disinfectant for use in food premises, hospitals and health care facilities, domestic locations and institutional and industrial premises.
University of North Carolina Lineberger Comprehensive Cancer Center researchers have found that by helping to form clots within tumors, immune cells that flock to a particular type of lung cancer are actually building a foundation for the tumor to spread within the body.
In a joint post in the Center for Global Development's (CGD) "Global Health Policy" blog, Amanda Glassman, director of global health policy and a senior fellow at the CGD; research assistant Denizhan Duran; and Kate McQueston, program coordinator to the global health policy team, recap major global health events in 2012, linking to previous coverage of highlighted issues.
Treatment with denosumab, a drug targeted against a protein that helps promote bone destruction, decreased the number of tumor giant cells in patients with giant-cell tumor of the bone, and increased new bone formation, according to the results of a phase II study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
› Verified 1 days ago
Vinay Ashok Shah, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 9821 S May Ave Ste C, Oklahoma City, OK 73159 Phone: 405-691-0505 Fax: 405-691-0507 | |
Cynthia A Bradford, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 608 Stanton L Young Blvd, Oklahoma City, OK 73104 Phone: 405-271-6060 Fax: 405-271-7873 | |
Jila Noorikolouri, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 608 Stanton L Young Blvd, Oklahoma City, OK 73104 Phone: 405-271-6060 Fax: 405-271-3013 | |
Dr. Brian Keith Firestone, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 608 Stanton L Young Blvd, Oklahoma City, OK 73104 Phone: 405-271-6060 Fax: 405-271-7873 | |
David W Parke Ii, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 608 Stanton L Young Blvd, Oklahoma City, OK 73104 Phone: 405-271-1092 | |
Gary Waine Wilson, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 7101 Nw Expressway, Suite 335, Oklahoma City, OK 73132 Phone: 405-722-2020 Fax: 405-516-6126 | |
David W. Jackson, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 608 Stanton L Young Blvd, Oklahoma City, OK 73104 Phone: 405-271-1095 |